Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Janssen-Cilag International
Homme Max 99 ans
Janssen-Cilag International NV Clinical Trial
MAJ Il y a 4 ans
A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single ascending doses as well as repeated doses of JNJ-42165279 in healthy male participants.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
MAJ Il y a 4 ans
A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia Protocol 37822681SCH2003; Phase IIa EudraCT Number: 2007-007669-20
The primary objective is to investigate the safety and tolerability of JNJ-37822681 administered as qd or bid following a dose titration in male and female patients with stable schizophrenia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression Estudio para evaluar la eficacia, seguridad y tolerabilidad de dosis flexibles de esketamina intranasal más un antidepresivo oral en sujetos adultos con depresión resistente al tratamiento
The primary objective of this study is to evaluate the efficacy of switching adult subjects with TRD from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
Safety of Rivaroxaban in patients with nonvalvular atrial fibrillation who undergo catheter ablation
The primary objective is to evaluate the safety of rivaroxaban and uninterrupted vitamin K antagonist (VKA) in adult subjects with nonvalvular atrial fibrillation (NVAF) who undergo catheter ablation ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants with Previously Treated Indolent Non-Hodgkin Lymphoma
The primary objective of this study is to evaluate whether the addition of ibrutinib to bendamustine and rituximab (BR) combination or rituximab, cyclophosphamide, doxorubicin, vincristine, and predni...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JNJ-39588146 in Subjects with Heart Failure Uno studio randomizzato, in doppio cieco, controllato con placebo, a gruppi paralleli per studiare la sicurezza, la tollerabilita`, la farmacodinamica e la farmacocinetica di JNJ-39588146 in soggetti con insufficienza cardiaca
Assess the hemodynamic effects, the safety and the tolerability of JNJ-39588146 when administered by intravenous infusion to male subjects and female subjects of non-childbearing potential with New Y...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Janssen-Cilag International N.V
MAJ Il y a 4 ans
CR100956 : Essai de phase 2, évaluant l’efficacité et la tolérance d’une thérapie ciblée, l’ibrutinib (PCI-32765), inhibiteur de la tyrosine kinase de Bruton, chez des patients ayant un lymphome folliculaire réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’ibrutinib, chez des patients ayant un lymphome folliculaire réfractaire ou en rechute après deux lignes de traitement. Les pati...
Pays
France
Organes
Lymphomes non hodgkinien
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants with Treatment-resistant Depression
The primary objective of this study is to evaluate the efficacy of switching elderly subjects with TRD from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intran...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
An Efficacy and Safety Study of JNJ56021927 (ARN509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
To determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy (RT) result...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Janssen-Cilag International NV
MAJ Il y a 4 ans
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
The primary objective of the study is to evaluate whether treatment with ibrutinib compared with temsirolimus will result in prolongation of PFS, as determined by blinded independent central review, i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant